Wall Street analysts expect Biopharmx Corp (NYSEAMERICAN:BPMX) to announce earnings per share (EPS) of ($0.11) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Biopharmx’s earnings. Biopharmx reported earnings per share of ($0.50) during the same quarter last year, which would suggest a positive year-over-year growth rate of 78%. The firm is expected to report its next quarterly earnings results on Thursday, December 5th.
According to Zacks, analysts expect that Biopharmx will report full year earnings of ($0.65) per share for the current financial year. For the next financial year, analysts expect that the business will post earnings of ($0.25) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Biopharmx.
Biopharmx (NYSEAMERICAN:BPMX) last announced its quarterly earnings data on Monday, September 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.11.
BPMX traded down $0.02 during trading on Thursday, hitting $0.35. The stock had a trading volume of 427,860 shares, compared to its average volume of 601,888. The company’s 50-day moving average price is $0.35 and its 200 day moving average price is $0.51. Biopharmx has a twelve month low of $0.30 and a twelve month high of $5.55.
An institutional investor recently bought a new position in Biopharmx stock. Nadler Financial Group Inc. acquired a new position in shares of Biopharmx Corp (NYSEAMERICAN:BPMX) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 45,000 shares of the biotechnology company’s stock, valued at approximately $27,000. Nadler Financial Group Inc. owned 0.52% of Biopharmx at the end of the most recent reporting period.
Biopharmx Company Profile
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Read More: Systematic Risk
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.